Forty-Year Journey of Angiogenesis Translational Research
2011 (English)In: Science Translational Medicine, ISSN 1946-6234, Vol. 3, no 114Article, review/survey (Refereed) Published
Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
Place, publisher, year, edition, pages
American Association for the Advancement of Science , 2011. Vol. 3, no 114
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-74155DOI: 10.1126/scitranslmed.3003149ISI: 000298322100001OAI: oai:DiVA.org:liu-74155DiVA: diva2:480864
Funding Agencies|Swedish Research Council||Swedish Cancer Foundation||Karolinska Institute Foundation||Karolinska Institute||Torsten Soderbergs Foundation||European Union of Metoxia|222741|European Research Council|250021|U.S. NIH|R01 CA118764-01P01 CA45548|ImClone Systems Inc./Eli Lilly||GlaxoSmithKline||2012-01-202012-01-202014-01-21Bibliographically approved